Rahul Gosain, MD

Results of the AGAVE-201 Study

Panelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

Overview of Chronic Graft-Versus-Host Disease, and AGAVE-201 Study Design

Panelists discuss what the AGAVE-201 study displayed.

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

Overview of Graft-Versus-Host Disease

Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

Exploring Outcomes From TROPION-Lung01 Presented at WCLC 2024

Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.

Rahul Gosain, MD;Rohit Gosain, MD;Gilberto Lopes, MD

HARMONi-02 Reveals Key Lung Cancer Insights at WCLC 2024

Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.

Rahul Gosain, MD;Rohit Gosain, MD;Gilberto Lopes, MD

WCLC 2024: Analyzing SKIPPirr Data Outcomes for Lung Cancer Advancements

Panelists discuss how the HARMONi-02 trial presented at World Conference on Lung Cancer 2024 revealed key lung cancer insights, focusing on progression-free survival and immune-related response criteria end points, while emphasizing the trial’s significance for specific patient subgroups.

Rahul Gosain, MD;Rohit Gosain, MD;Gilberto Lopes, MD

Highlights from WCLC 2024: CheckMate -77T vs. CheckMate -816

Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.

Rahul Gosain, MD;Rohit Gosain, MD;Gilberto Lopes, MD

Recent Data from COMMIT in dMMR/MSI-High Metastatic Colorectal Cancer

Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, potentially revolutionizing treatment strategies and enhancing long-term survival rates for patients with lung cancer.

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

COLLISION: Surgery vs Thermal Ablation for Small-Size Colorectal Liver Mets

Mark A. Lewis, MD, discusses recent data from the COMMIT trial investing first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

TRANSMET: Chemotherapy Plus Liver Transplant in Unresectable Colorectal Liver Metastases

The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Cancer

Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

Recent Updates from the ESOPEC Trial in Esophageal Adenocarcinoma

Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

PSMAfore: Health-Related QoL and Pain in Taxane-Naïve Patients with mCRPC

Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

Real-World Evidence from the IMDC

Toni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

KIM-1: Biomarker Analysis in IMmotion010 in RCC

Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

The Role of ctDNA in Genitourinary Cancer

Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer

Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

Key Updates from DESTINY-Breast06

Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated Breast Cancer

Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

Recent Updates from the postMONARCH Study

Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

RxPONDER: Use of AMH Levels in Premenopausal Women

The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

ADRIATIC: Durvalumab as Consolidation Treatment for Limited-Stage SCLC

Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.

The Oncology Brothers with Joshua K. Sabari, MD, presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

Results from CROWN: Lorlatinib in Treatment-Naïve Patients with Advanced ALK+ NSCLC

Joshua K. Sabari, MD, and the Oncology Brothers discuss recent findings from the ADRIATIC study focused on durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

PALOMA-3: Subcutaneous Amivantamab in Refractory EGFR-Mutated Advanced NSCLC

The Oncology Brothers and Joshua K. Sabari, MD, provide expert perspectives on recent updates from the CROWN trial investigating lorlatinib in treatment-naïve advanced ALK+ non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

Recent Updates from MARIPOSA on Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC

Expert perspectives on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

LAURA: Osimertinib after Definitive CRT in Unresectable Stage III NSCLC with EGFR Mutations

Joshua K. Sabari, MD, discusses recent updates from the MARIPOSA study, which is investigating amivantamab plus lazertinib in the first line in patients with EGFR-mutated advanced non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD